Right back at you, Pfizer: BeiGene and a Pfizer spinout launch a newco to develop a MEK/BRAF inhibitor that could rival $11.4B combo
A day after Pfizer bought Array and its approved cancer combo, BeiGene and Pfizer spinout SpringWorks have partnered in launching a new biotech that has an eye on the very same market the pharma giant just paid billions for. And they’re planning on using an ex-Pfizer drug to do it.
In a nutshell, China’s BeiGene is tossing in a preclinical BRAF inhibitor — BGB-3245, which covers both V600 and non-V600 BRAF mutations — for a big stake in a new, jointly controlled biotech called MapKure with Bain-backed SpringWorks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.